Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3956276 | 0.87 | GPR119 (0.54) | GPR119ALDH1A1TACR1POLBDTYMK | |
| SCHEMBL30793467 | 0.84 | GPR119 (0.51) | GPR119ALDH1A1TACR1POLBMEN1 | |
| SCHEMBL5428790 | 0.81 | ALDH1A1 (0.47) | HSD17B10CYP2D6ALDH1A1CYP3A4TSHR | |
| SCHEMBL30585014 | 0.80 | CYP46A1 (0.54) | GPR119HSD17B10CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL1088021 | 0.80 | CYP46A1 (0.54) | GPR119HSD17B10CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL25400769 | 0.79 | GPR119 (0.50) | GPR119ALDH1A1TACR1OPRD1OPRK1 | |
| SCHEMBL22941868 | 0.79 | HSD17B10 (0.69) | CYP11B2GPR119HSD17B10CYP2D6ALDH1A1 | |
| SCHEMBL29506047 | 0.79 | GPR119 (0.50) | GPR119HSD17B10CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL20137533 | 0.79 | GPR119 (0.50) | GPR119HSD17B10CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL484915 | 0.79 | HSD17B10 (0.65) | CYP11B2GPR119HSD17B10CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249648-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249648-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249648-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| EP-1678178-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | AstraZeneca AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005040167-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249648-A1 | Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases | CCR8, CCR1, CCR10 | CYP11B2 1965/4885GPR119 318/4885HSD17B10 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.